Initiation of Androgen Deprivation Therapy for Prostate Cancer Using Degarelix Followed by Leuprolide

Completed · Not applicable

Conditions studied: Prostate Cancer

In brief

The purpose of this study is to determine if patients initiating androgen deprivation therapy (ADT) for prostate cancer can be transitioned from degarelix acetate to leuprolide acetate after an initial three-month period without a rise in serum testosterone. The investigators expect testosterone will quickly and reliably reach castrate levels after initiation of ADT and will remain castrate during the transition, and there will be no "testosterone surge" after leuprolide injection.

Key facts

Study ID

NCT01344564

Run by

Urology of Virginia

People needed

50

Starts

2011-04-01

Expected to finish

2012-08-01

Last updated by the study team

2013-03-18

Who can join

Age: 18 and older. Sex: male. Healthy volunteers: not accepted.

You may qualify if…

• 18 years or older
• Histologically confirmed adenocarcinoma of the prostate
• Androgen deprivation therapy is indicated

You may not qualify if…

• Baseline screening serum testosterone <150ng/dL
• Eastern Cooperative Oncology Group (ECOG) score > 2
• Diagnosed spinal or brain metastases
• Hormonal manipulation within previous 6 months

Where it is running

• Urology of Virginia — Virginia Beach, Virginia, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.